Acute coronary syndrome in very elderly patients-a real-world experience

被引:4
|
作者
Bianco, Matteo [1 ]
Mottola, Filiberto Fausto [2 ]
Cerrato, Enrico [1 ]
Giordana, Francesca [3 ]
Cinconze, Sebastian [3 ]
Baralis, Giorgio [3 ]
Verra, Alison [3 ]
Musumeci, Giuseppe [4 ]
Rossini, Roberta [3 ]
机构
[1] San Luigi Gonzaga Univ Hosp, Div Cardiol, Orbassano, Turin, Italy
[2] Univ Campania Luigi Vanvitelli, Monaldi Hosp, Chair Cardiol, Dept Translat Med Sci, Naples, Italy
[3] S Croce & Carle Hosp, Div Cardiol, Via Michele Coppino 26, I-12100 Cuneo, Italy
[4] Ordine Mauriziano Torino Hosp, Div Cardiol, Turin, Italy
关键词
Very elderly; Acute coronary syndromes; Percutaneous coronary intervention; Real world; ACUTE MYOCARDIAL-INFARCTION; GLOBAL REGISTRY; HOSPITAL MORTALITY; RISK SCORE; CLOPIDOGREL; INTERVENTION; DEFINITION; TICAGRELOR; MANAGEMENT; PRASUGREL;
D O I
10.1007/s00380-023-02260-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Very elderly population constitutes an increasingly larger proportion of patients admitted for acute coronary syndromes (ACS). Notably, age represents both a proxy of frailty and an exclusion criterion in clinical randomized trials, which probably contributes to lack of data and undertreatment of real-world elderly patients. The aim of the study is to describe patterns of treatment and outcome of very elderly patients with ACS. All consecutive patients aged >= 80 years old (yo) admitted between January 2017 and December 2019 with ACS were included. The primary endpoint was in-hospital occurrence of major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, new onset cardiogenic shock, definite/probable stent thrombosis, and ischemic stroke. The secondary endpoints were in-hospital incidence of Thrombolysis in Myocardial Infarction (TIMI) major/minor bleedings, contrast-induced nephropathy (CIN), six-month all-cause mortality, and unplanned readmission. One hundred ninety-three patients (mean age 84.1 +/- 3.5 yo, 46% females) were included, of whom 86 (44.6%), 79 (40.9%), and 28 (14.5%) presented with ST elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina (UA), respectively. The vast majority of patients received an invasive strategy, with 92.7% undergoing coronary angiography and 84.4% to percutaneous coronary intervention (PCI). Aspirin was administered to 180 (93.3%) patients, clopidogrel to 89 (46.1%) patients, and ticagrelor to 85 (44%) patients. In-hospital MACE occurred in 29 patients (15.0%), whereas 3 (1.6%) and 12 patients (7.2%) experienced in-hospital TIMI major and TIMI minor bleeding, respectively. Of the overall population, 177 (91.7%) were discharged alive. After discharge, 11 patients (6.2%) died of all-cause death, whereas 42 patients (23.7%) required a new hospitalization within six months. Invasive strategy of ACS in elderly patients seems safe and effective. Six-month new hospitalization appears inevitably related to age.
引用
收藏
页码:1019 / 1027
页数:9
相关论文
共 50 条
  • [21] The effect of coronary stent policies on the risk of percutaneous coronary intervention among acute coronary syndrome patients in Shanghai: Real-world evidence
    Shao, Zhenyi
    Lu, Dongzhe
    Wang, Yue
    Xue, Di
    [J]. PLOS ONE, 2024, 19 (04):
  • [22] INCIDENCE OF NON-ACUTE CORONARY SYNDROME DIAGNOSES IN PATIENTS WITH MILDLY ABNORMAL HIGH-SENSITIVITY TROPONIN: A REAL-WORLD US EXPERIENCE
    Khan, Arooj R.
    Cremer, Paul
    Jaber, Wael
    Hu, Peter
    Gonzalez, Daniel
    Menon, Venu
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 17 - 17
  • [23] Outcome of mechanical thrombectomy in the very elderly for the treatment of acute ischemic stroke: the real world experience
    To, Chiu Yuen
    Rajamand, Sina
    Mehra, Ratnesh
    Falatko, Stephanie
    Badr, Yaser
    Richards, Boyd
    Qahwash, Omar
    Fessler, Richard D.
    [J]. ACTA RADIOLOGICA OPEN, 2015, 4 (09)
  • [24] Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States
    Bae, Jay P.
    Faries, Douglas E.
    Ernst, Frank R.
    Lipkin, Craig
    Zhao, Zhenxiang
    Moretz, Chad
    Lieu, Hsiao D.
    Effron, Mark B.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (11) : 2207 - 2216
  • [25] The perils of polyvascular disease with concomitant type 2 diabetes in a real-world cohort of patients with acute coronary syndrome
    Denegri, A.
    Magnani, G.
    Rossi, V. A.
    Raeber, L.
    Windecker, S.
    Gencer, B.
    Mach, F.
    Rodondi, N.
    Heg, D.
    Nanchen, D.
    Matter, C. M.
    Luescher, T. F.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 4040 - 4040
  • [26] Clinical trial-derived risk model may not generalize to real-world patients with acute coronary syndrome
    Yan, AT
    Jong, P
    Yan, RT
    Tan, M
    Fitchett, D
    Chow, CM
    Roe, MT
    Pieper, KS
    Langer, A
    Goodman, SG
    [J]. AMERICAN HEART JOURNAL, 2004, 148 (06) : 1020 - 1027
  • [27] Real-World Use and Outcomes of Oral Antiplatelets Among Patients with Acute Coronary Syndrome: A Retrospective Cohort Study
    Samuel K. Peasah
    Douglas Mager
    Kiraat D. Munshi
    Yan Huang
    Rochelle Henderson
    Elizabeth C. S. Swart
    Lynn Neilson
    Chester B. Good
    [J]. Drugs - Real World Outcomes, 2022, 9 : 121 - 127
  • [28] Real-World Use and Outcomes of Oral Antiplatelets Among Patients with Acute Coronary Syndrome: A Retrospective Cohort Study
    Peasah, Samuel K.
    Mager, Douglas
    Munshi, Kiraat D.
    Huang, Yan
    Henderson, Rochelle
    Swart, Elizabeth C. S.
    Neilson, Lynn
    Good, Chester B.
    [J]. DRUGS-REAL WORLD OUTCOMES, 2022, 9 (01) : 121 - 127
  • [29] A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia
    Hu, Rong-Hua
    Su, Li
    Lan, Xiao-Xi
    Chang, Xiao-Li
    Hui, Wu-Han
    Guo, Yi-Xian
    Zhao, Hong
    Zhang, Yue
    Sun, Wan-Ling
    [J]. ANTI-CANCER DRUGS, 2023, 34 (03) : 344 - 350
  • [30] Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia
    Winters, Amanda C.
    Gutman, Jonathan A.
    Purev, Enkhtsetseg
    Nakic, Molly
    Tobin, Jennifer
    Chase, Stephanie
    Kaiser, Jeff
    Lyle, Lindsey
    Boggs, Chelsey
    Halsema, Keri
    Schowinsky, Jeffrey T.
    Rosser, Julie
    Ewalt, Mark D.
    Siegele, Bradford
    Rana, Vishal
    Schuster, Steven
    Abbott, Diana
    Stevens, Brett M.
    Jordan, Craig T.
    Smith, Clayton
    Pollyea, Daniel A.
    [J]. BLOOD ADVANCES, 2019, 3 (20) : 2911 - 2919